支持血管外科学会间歇性跛行管理指南更新的系统综述
该研究为血管外科学会指南更新而开展系统综述与Meta分析,检索MEDLINE、EMBASE等数据库,纳入73项研究(46项随机试验),评估药物治疗、运动方案、腔内干预及不良事件预测因素。结果显示,在高危合并症患者中低剂量利伐沙班联合阿司匹林较单用阿司匹林可降低主要不良肢体事件和主要不良心血管事件风险;家庭运动方案可行,或可替代监督运动;股浅动脉中长病变(>5 cm)普通球囊血管成形术结局劣于药物洗脱或支架植入。
要点
- 高危合并症患者中,低剂量利伐沙班联合阿司匹林较单用阿司匹林降低主要不良肢体和心血管事件风险。
- 家庭运动方案可行,或可替代监督运动用于门诊间歇性跛行患者及血运重建后患者。
- 股浅动脉中长病变(>5 cm)普通球囊血管成形术结局劣于药物洗脱或支架植入。
核心结论
- 系统综述总结了间歇性跛行管理的当前证据,提示需根据不同干预的潜在获益与风险进行个体化患者管理。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE、Cochrane对照试验中心注册库、Cochrane系统综述数据库和Scopus,由血管外科学会指南委员会提出六个问题。
- 共检索到5333条引文,最终纳入73项研究,其中46项为随机试验。
主要发现
- 在具有一种或多种高危合并症的间歇性跛行患者中,低剂量利伐沙班联合阿司匹林与单用阿司匹林相比,主要不良肢体事件和主要不良心血管事件风险更低。
- 已接受手术或腔内干预的间歇性跛行患者中,在阿司匹林基础上加用低剂量利伐沙班可能改善肢体结局。
- 单种抗血小板药物在门诊间歇性跛行患者头对头比较中疗效无显著差异,且与联合治疗或抗凝相比出血风险更低。
- 家庭运动方案可行,或可替代监督运动用于门诊间歇性跛行患者及血运重建后患者。
- 股浅动脉中长病变(即>5 cm)行腔内干预时,普通球囊血管成形术结局劣于药物洗脱或支架植入。
关键数值与推荐
- 高龄、糖尿病、冠心病、慢性阻塞性肺疾病、既往干预、充血性心力衰竭、膝下动脉受累和病变长度较长等合并症增加间歇性跛行血运重建后不良结局风险。
- 利伐沙班试验排除了高出血风险患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 利伐沙班试验排除了高出血风险患者。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This systematic review and meta-analysis evaluates the current evidence on the management of intermittent claudication (IC), a prevalent manifestation of peripheral arterial disease (PAD). METHODS: We conducted comprehensive searches of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. We addressed six questions developed by a guideline committee from the Society for Vascular Surgery, addressing pharmacological treatments, exercise regimens, endovascular interventions, and predictors of major adverse cardiovascular, limb-related events, and mortality. RESULTS: The search resulted in 5333 citations, from which we included 73 studies (46 randomized trials). In patients with PAD and IC who had one or more high-risk comorbidities, low-dose rivaroxaban and aspirin were associated with lower risk of major adverse limb events and major adverse cardiovascular events than aspirin alone. In patients who have undergone surgical or endovascular interventions for PAD, the addition of low-dose rivaroxaban to aspirin may improve limb outcomes. Of note, rivaroxaban trials excluded patients at high risk of bleeding. Single antiplatelet agents showed no significant efficacy differences head-to-head in ambulatory patients with IC and had a lower bleeding risk compared with combination therapy or anticoagulation. Home exercise programs were feasible and may be an alternative to supervised exercise in ambulatory patients with IC and in those who had revascularization. Several comorbidities increased the risk of adverse outcomes after revascularization for IC, such as advanced age, diabetes, coronary artery disease, chronic obstructive pulmonary disease, previous interventions, congestive heart failure, infrapopliteal artery involvement, and longer lesion lengths. In patients with IC undergoing endovascular intervention for superficial femoral artery disease, plain balloon angioplasty was associated with worse outcomes than drug elution or stent implantation for intermediate or longer lesions (ie, >5 cm). CONCLUSIONS: This systematic review summarizes the current evidence base for the management of IC, offering insights into the relative benefits and risks of various therapeutic strategies. The findings underscore the need for individualized patient care, considering both the potential benefits and risks associated with different interventions.
引用
- Saadi S, Nayfeh T, Rajjoub R, et al. A systematic review supporting the Society for Vascular Surgery guideline update on the management of intermittent claudication. J Vasc Surg. 2025. PMID: 40316186. doi:10.1016/j.jvs.2024.12.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。